natgillin/translations-raw huggingface dataset:
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Amlodipine/Valsartan Mylan.
Grejp i sok od grejpa u nekih bolesnika može dovesti do povećanja razina djelatne tvari amlodipina u krvi, što može uzrokovati neočekivano pojačani učinak lijeka Amlodipin/Valsartan Mylan na snižavanje krvnog tlaka.
For the single compounds there was no evidence of mutagenicity, clastogenicity or carcinogenicity.
Nije bilo dokaza mutagenosti, klastogenosti ni kancerogenosti pojedinačnih komponenti.
Amlodipine/Valsartan Mylan is used to treat high blood pressure in adults whose blood pressure is not controlled enough with either amlodipine or valsartan on its own.
Amlodipin/Valsartan Mylan se primjenjuje za liječenje povišenog krvnog tlaka u odraslih osoba čiji krvni tlak nije dovoljno kontroliran bilo samo amlodipinom ili samo valsartanom.
Other possible side effects of Amlodipine/Valsartan Mylan:
Ostale moguće nuspojave lijeka Amlodipin/Valsartan Mylan:
Excessive hypotension was seen in 0.4 % of patients with uncomplicated hypertension treated with amlodipine/valsartan in placebo-controlled studies.
U placebo-kontroliranim ispitivanjima, u 0,4% bolesnika s nekompliciranom hipertenzijom liječenih amlodipinom/valsartanom viđena je izražena hipotenzija.
There is a risk of increased tacrolimus blood levels when co administered with amlodipine.
Postoji rizik od povišene razine takrolimusa u krvi kada se primjenjuje istodobno s amlodipinom.
Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Amlodipin/Valsartan Mylan je indiciran u odraslih osoba čiji krvni tlak nije odgovarajuće kontroliran monoterapijom amlodipinom ili valsartanom.
Pharyngolaryngeal pain
Faringolaringealna bol
These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m basis (calculations assume an oral dose of
Takve doze u štakora (200 i 600 mg/kg/dan) otprilike su 6 i 18 puta veće od najviše preporučene doze za ljude izražene u mg/m
In this study (baseline blood pressure 171/113 mmHg), an amlodipine/valsartan regimen of 5 mg/160 mg titrated to 10 mg/160 mg reduced sitting blood pressure by 36/29 mmHg as compared to 32/28 mmHg with a regimen of lisinopril/hydrochlorothiazide 10 mg/12.5 mg titrated to 20 mg/12.5 mg.
U tom ispitivanju (početni krvni tlak 171/113 mmHg), liječenje amlodipinom/valsartanom 5 mg/160 mg titriranim do 10 mg/160 mg snizilo je krvni tlak u sjedećem položaju za 36/29 mmHg, u usporedbi s 32/28 mmHg kod liječenja lizinoprilom/hidroklorotiazidom 10 mg/12,5 mg titriranim do 20 mg/12,5 mg.
Side effects reported with amlodipine or valsartan alone and either not observed with Amlodipine/Valsartan Mylan or observed with a higher frequency than with Amlodipine/Valsartan Mylan:
Prijavljene nuspojave s amlodipinom ili valsartanom primijenjenima samostalno ili uopće nisu opažene s lijekom Amlodipin/Valsartan Mylan ili su opažene s većom učestalošću nego s lijekom Amlodipin/Valsartan Mylan:
Somnolence, dizziness, palpitations, abdominal pain, nausea, ankle swelling.
Somnolencija, omaglica, palpitacije, bol u abdomenu, mučnina, oticanje gležnjeva.
Similar changes were also seen in the valsartan alone group (exposure 8.5-11.0 times the clinical dose of 160 mg valsartan).
Slične promjene su također viđene u skupini koja je bila samo na valsartanu (izloženost 8,5-11,0 puta veća od izloženosti kliničkom dozom od 160 mg valsartana).
Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, hypertonia, peripheral neuropathy, myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation), vasculitis, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, hepatic enzymes increased*, angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity.
Vrlo rijetko Leukocitopenija, trombocitopenija, alergijske reakcije, hiperglikemija, hipertonija, periferna neuropatija, infarkt miokarda, aritmija (uključujući bradikardiju, ventrikularnu tahikardiju i fibrilaciju atrija), vaskulitis, pankreatitis, gastritis, hiperplazija gingive, hepatitis, žutica, povišenje jetrenih enzima*, angioedem, multiformni eritem, urtikarija, eksfolijativni dermatitis, Stevens-Johnsonov sindrom, Quinckeov edem, fotosenzitivnost.
The MAH must ensure that the manufacturing processes of the drug substances used for their drug products are reviewed for the potential risk of formation of N
Nositelj odobrenja za stavljanje lijeka u promet mora osigurati da se pregledaju proizvodni procesi djelatnih tvari njegovih lijekova kako bi se utvrdio potencijalni rizik od nastanka N-nitrozamina te da se prema potrebi promijene kako bi se kontaminacija nitrozaminom svela na najmanju moguću mjeru.
Amlodipine/Valsartan Mylan can be used with or without food.
Amlodipin/Valsartan Mylan se može primjenjivati s hranom ili bez nje.
When switching eligible elderly hypertensive patients (see section 4.1) to amlodipine or amlodipine/valsartan, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
Prilikom prebacivanja starijih hipertenzivnih bolesnika koji ispunjavaju uvjete za liječenje (vidjeti dio 4.1) na amlodipin ili amlodipin/valsartan, treba se koristiti najniža dostupna doza amlodipina u monoterapiji ili amlodipina kao komponente.
The active substances of Amlodipine/Valsartan Mylan are amlodipine (as amlodipine besilate) and valsartan.
Djelatne tvari u lijeku Amlodipin/Valsartan Mylan su amlodipin (u obliku amlodipinbesilata) i valsartan.
If you take more Amlodipine/Valsartan Mylan than you should If you have taken too many tablets of Amlodipine/Valsartan Mylan, or if someone else has taken your tablets, consult a doctor immediately.
Ako ste uzeli previše tableta lijeka Amlodipin/Valsartan Mylan, ili ako je netko drugi uzeo Vaše tablete, odmah se posavjetujte s liječnikom.
Caution should be exercised when administering amlodipine/valsartan to patients with hepatic impairment or biliary obstructive disorders (see section 4.4).
Nužan je oprez kod primjene amlodipina/valsartana bolesnicima s oštećenjem jetre ili opstruktivnim bolestima žučnog sustava (vidjeti dio 4.4).
What Amlodipine/Valsartan Mylan contains
Što Amlodipin/Valsartan Mylan sadrži
Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS) Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an angiotensin II receptor blocker (ARB).
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) i VA NEPHRON-D (eng. The Veterans Affairs Nephropathy in Diabetes)) ispitivala su primjenu kombinacije ACE inhibitora s blokatorima angiotenzin II receptora (ARB-ovima).
Amlodipine dosage recommendations have not been established in patients with mild to moderate hepatic impairment.
Preporučeno doziranje amlodipina nije ustanovljeno u bolesnika s blagim do umjerenim oštećenjem jetre.
Similar changes were found in the valsartan alone group (exposure 8.5-11.0 times the clinical dose of 160 mg valsartan).
Slične su promjene nađene i u skupini koja je bila samo na valsartanu (izloženost 8,511,0 puta viša od izloženosti kliničkom dozom od 160 mg valsartana).
When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or amlodipine/valsartan, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
Prilikom prebacivanja hipertenzivnih bolesnika koji ispunjavaju uvjete za liječenje (vidjeti dio 4.1) s oštećenjem jetre na amlodipin ili amlodipin/valsartan, treba se koristiti najniža dostupna doza amlodipina u monoterapiji ili amlodipina kao komponente.
Particular caution should be exercised when administering amlodipine/valsartan to patients with mild to moderate hepatic impairment or biliary obstructive disorders.
Nužan je poseban oprez kod primjene amlodipina/valsartana bolesnicima s blagim do umjerenim oštećenjem jetre ili opstruktivnim poremećajima žučnog sustava.
Candesartan 32 * These limits are not applicable for batches where more than one of the above N-nitrosamines has been identified simultaneously; such batches should be rejected.
valsartan 320 losartan 150 olmesartan 40 irbesartan 300 kandesarta n * Te granične vrijednosti nisu primjenjive za serije gdje je utvrđeno istodobno postojanje više od jednog od prethodno navedenih N-nitrozamina; takve serije treba odbaciti.
Very rare (may affect up to 1 in 10,000 people): Decreased number of white blood cells, decrease in blood platelets which may result in unusual bruising or easy bleeding (red blood cell damage); excess sugar in blood (hyperglycaemia); swelling of the gums, abdominal bloating (gastritis); abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests; increased muscle tension; inflammation of blood vessels often with skin rash, sensitivity to light;
Vrlo rijetko (mogu se javiti u do 1 na 10 000 osoba): Smanjen broj bijelih krvnih stanica, smanjen broj krvnih pločica što može rezultirati stvaranjem neuobičajenih modrica ili lakog krvarenja (oštećenje crvenih krvnih stanica); povišen šećer u krvi (hiperglikemija), oticanje desni, nadutost u trbuhu (gastritis), nepravilna jetrena funkcija, upala jetre (hepatitis), žutilo kože (žutica), povišeni jetreni enzimi što može imati učinak na neke medicinske testove, povećana napetost mišića, upala krvnih žila često s kožnim osipom, osjetljivost na svjetlost.
You can take Amlodipine/Valsartan Mylan with or without food.
Amlodipin/Valsartan Mylan možete uzimati s hranom ili bez nje.
The effect of amlodipine/valsartan on infants is unknown.
Učinak amlodipina na dojenčad nije poznat.
Posology The recommended dose of Amlodipine/Valsartan Mylan is one tablet per day.
Preporučena doza lijeka Amlodipin/Valsartan Mylan je jedna tableta na dan.
A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on amlodipine 10 mg in 78 % of patients treated with amlodipine/valsartan 10 mg/160 mg, compared to 67 % of patients remaining on amlodipine 10 mg.
Multicentrično, randomizirano, dvostruko slijepo, aktivno kontrolirano ispitivanje paralelnih skupina je u bolesnika, koji nisu bili odgovarajuće kontrolirani amlodipinom 10 mg, pokazalo normalizaciju krvnog tlaka (donja vrijednost dijastoličkog krvnog tlaka u sjedećem položaju <90 mmHg na kraju ispitivanja) u 78% bolesnika liječenih amlodipinom/valsartanom 10 mg/160 mg, u usporedbi s 67% bolesnika koji su ostali na amlodipinu 10 mg.
Common (may affect up to 1 in 10 people): Influenza (flu); blocked nose, sore throat and discomfort when swallowing; headache; swelling of arms, hands, legs, ankles or feet; tiredness; asthenia (weakness); redness and warm feeling of the face and/or neck.
Česte (mogu se javiti u do 1 na 10 osoba): Influenca (gripa); začepljen nos, grlobolja i osjećaj nelagode pri gutanju; glavobolja; oticanje ruku, šaka, nogu, gležnjeva ili stopala; umor; astenija (slabost); crvenilo i osjećaj topline u licu i/ili vratu.
Hypromellose Titanium dioxide (E171) Macrogol 8000
Ovojnica: hipromeloza titanijev dioksid (E171) makrogol 8000 talk žuti željezov oksid (E172)
Active-controlled trials in patients who were non-responders to monotherapy A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on valsartan 160 mg in 75 % of patients treated with amlodipine/valsartan 10 mg/160 mg and 62 % of patients treated with amlodipine/valsartan 5 mg/160 mg, compared to 53 % of patients remaining on valsartan 160 mg.
Multicentrično, randomizirano, dvostruko slijepo, aktivno kontrolirano ispitivanje paralelnih skupina je u bolesnika, koji nisu bili odgovarajuće kontrolirani valsartanom 160 mg, pokazalo normalizaciju krvnog tlaka (donja vrijednost dijastoličkog krvnog tlaka u sjedećem položaju <90 mmHg na kraju ispitivanja) u 75% bolesnika liječenih amlodipinom/valsartanom 10 mg/160 mg i 62% bolesnika liječenih amlodipinom/valsartanom 5 mg/160 mg, u usporedbi s 53% bolesnika koji su ostali na valsartanu 160 mg.
Uncommon (may affect up to 1 in 100 people): Mood changes, anxiety, depression, sleeplessness, trembling, taste abnormalities, fainting, loss of pain sensation; visual disturbances, visual impairment, ringing in the ears; low blood pressure; sneezing/runny nose caused by inflammation of the lining of the nose (rhinitis); indigestion, vomiting (being sick); hair loss, increased sweating, itchy skin, skin discolouration; disorder in passing urine, increased need to urinate at night, increased number of times of passing urine; inability to obtain an erection, discomfort or enlargement of the breasts in men, pain, feeling unwell, muscle pain, muscle cramps; weight increase or decrease.
Manje često (mogu se javiti u do 1 na 100 osoba): Promjene raspoloženja, tjeskoba, depresija, pospanost, drhtanje, poremećaji okusa, nesvjestica, gubitak osjećaja boli; poremećaji vida, oštećenje vida, zvonjava u ušima; niski krvni tlak; kihanje/curenje iz nosa uzrokovano upalom sluznice nosa (rinitis); loša probava, povraćanje; ispadanje kose, pojačano znojenje, svrbljiva koža, promjena boje kože; poremećaj mokrenja, pojačana potreba za mokrenjem noću, povećan broj mokrenja, nemogućnost postizanja erekcije, nelagoda ili povećanje dojki u muškaraca, bol, loše osjećanje, bol u mišićima, grčevi u mišićima; povećanje ili smanjenje tjelesne težine.
Rare (may affect up to 1 in 1,000 people): Feeling anxious; ringing in the ears (tinnitus); fainting; passing more urine than normal or feeling more of an urge to pass urine; inability to get or maintain an erection; sensation of heaviness; low blood pressure with symptoms such as dizziness, lightheadedness; excessive sweating; skin rash all over your body; itching; muscle spasm.
Rijetke (mogu se javiti u do 1 na 1000 osoba): Osjećaj tjeskobe; zvonjava u ušima (tinitus); nesvjestica; pojačano mokrenje ili pojačan nagon na mokrenje; nemogućnost postizanja ili održavanja erekcije; osjećaj težine; niski krvni tlak sa simptomima poput omaglice, omamljenosti; pojačanog znojenja; kožni osip po čitavom tijelu; svrbež; grč mišića.
Consult a doctor immediately if you experience any of the following very rare, severe side effects after taking this medicine:
Odmah se javite liječniku ako osjetite bilo koju od sljedećih vrlo rijetkih, teških nuspojava nakon uzimanja ovog lijeka: - Iznenadno piskanje pri disanju, bol u prsima, nedostatak zraka ili otežano disanje.
Your doctor may also check your kidney function; anticonvulsant agents (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone); St. John's wort; nitroglycerin and other nitrates, or other substances called “vasodilators”;
Liječnik će Vam možda provjeriti i bubrežnu funkciju; antikonvulzivni lijekovi (npr. karbamazepin, fenobarbital, fenitoin, fosfenitoin, primidon);
How to take Amlodipine/Valsartan Mylan
Kako uzimati Amlodipin/Valsartan Mylan
The other ingredients are cellulose microcrystalline; crospovidone; magnesium stearate; silica colloidal anhydrous; hypromellose; macrogol 8000; talc, titanium dioxide (E171); iron oxide yellow (E172).
Drugi sastojci su mikrokristalična celuloza, krospovidon, magnezijev stearat, koloidni bezvodni silicijev dioksid, hipromeloza, makrogol 8000, talk, titanijev dioksid (E171), žuti željezov oksid (E172).
The other ingredients are cellulose microcrystalline; crospovidone; magnesium stearate; silica colloidal anhydrous; hypromellose; macrogol 8000; talc; titanium dioxide (E171); iron oxide yellow (E172); iron oxide red (E172); iron oxide black (E172).
Drugi sastojci su mikrokristalična celuloza, krospovidon, magnezijev stearat, koloidni bezvodni silicijev dioksid, hipromeloza, makrogol 8000, talk, titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172), crni željezov oksid (E172).
Uncommon (may affect up to 1 in 100 people): Dizziness; nausea and abdominal pain; dry mouth; drowsiness, tingling or numbness of the hands or feet; vertigo; fast heart beat including palpitations; dizziness on standing up; cough; diarrhoea; constipation; skin rash, redness of the skin; joint swelling, back pain; pain in joints.
Manje česte (mogu se javiti u do 1 na 100 osoba): Omaglica; mučnina i bol u trbuhu; suha usta; omamljenost, trnci ili obamrlost šaka ili stopala; vrtoglavica; ubrzani otkucaji srca, uključujući osjećaj lupanja srca; omaglica kod ustajanja; kašalj; proljev; zatvor; kožni osip, crvenilo kože; oticanje zglobova, bol u leđima; bol u zglobovima.
Renal impairment There are no available clinical data in severely renally impaired patients.
Oštećenje bubrega Klinički podaci u bolesnika s teškim oštećenjem bubrega nisu dostupni.
NDEA Limit in ppm in API
NDMA Granična vrijednost u aktivnim farmaceutski m sastojcima (ppm)
Iron oxide yellow (E172) Iron oxide red (E172) Iron oxide black (E172)
Ovojnica: hipromeloza titanijev dioksid (E171) makrogol 8000 talk žuti željezov oksid (E172) crveni željezov oksid (E172) crni željezov oksid (E172)
amlodipine/valsartan mylan 5 mg/80 mg
amlodipin/valsartan mylan 5 mg/80 mg
Amlodipine/valsartan should be discontinued immediately in patients who develop angioedema and should not be re-administered.
Bolesnici u kojih se razvije angioedem trebaju odmah prekinuti primjenu amlodipina/valsartana i više ga ne smiju ponovo uzimati.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Amlodipine/Valsartan Mylan 5 mg/160 mg.
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg može se primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 10 mg ili valsartanom 160 mg ili lijekom Amlodipin/Valsartan Mylan 5 mg/160 mg.
Extrapyramidal disorder
Ekstrapiramidalni poremećaj
Each tablet contains 5 mg amlodipine (as amlodipine besilate) and 80 mg valsartan.
Jedna tableta sadrži 5 mg amlodipina (u obliku amlodipinbesilata) i 80 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/80 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 80 mg.
amlodipine/valsartan Mylan 10 mg/160 mg
amlodipin/valsartan mylan 10 mg/160 mg
How to store Amlodipine/Valsartan Mylan
Kako čuvati Amlodipin/Valsartan Mylan
amlodipine/valsartan mylan 5 mg/160 mg
amlodipin/valsartan mylan 5 mg/160 mg
Other medicines and Amlodipine/Valsartan Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Common (may affect up to 1 in 10 people): Dizziness, sleepiness; palpitations (awareness of your heart beat); flushing, ankle swelling (oedema); abdominal pain, feeling sick (nausea).
Često (mogu se javiti u do 1 na 10 osoba): Omaglica, pospanost; palpitacije (svijest o radu Vašeg srca); crvenilo uz osjećaj vrućine, oticanje gležnjeva (edem); bol u trbuhu, mučnina.
Each tablet contains 10 mg amlodipine (as amlodipine besilate) and 160 mg valsartan.
Jedna tableta sadrži 10 mg amlodipina (u obliku amlodipinbesilata) i 160 mg valsartana.
Fertility There are no clinical studies on fertility with amlodipine/valsartan.
Ne postoje klinička ispitivanja djelovanja amlodipina/valsartana na plodnost.
Amlodipine Common
Amlodipin Često
Each tablet contains 5 mg amlodipine (as amlodipine besilate) and 160 mg valsartan.
Jedna tableta sadrži 5 mg amlodipina (u obliku amlodipinbesilata) i 160 mg valsartana.
If you think you may be allergic, talk to your doctor before taking Amlodipine/Valsartan Mylan.
Ako mislite da biste mogli biti alergični, porazgovarajte sa svojim liječnikom prije uzimanja lijeka Amlodipin/Valsartan Mylan. ako imate teške probleme s jetrom ili probleme sa žuči, poput bilijarne ciroze ili kolestaze.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg može se primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 160 mg.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker (ARB) in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
ALTITUDE (eng. Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) je bilo ispitivanje osmišljeno za testiranje koristi dodavanja aliskirena standardnoj terapiji s
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets amlodipine/valsartan
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg tablets are light brown, oval, biconvex film-coated tablet marked with “AV3” on one side and “M” on the other side.
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg tablete su svjetlosmeđe, ovalne, bikonveksne filmom obložene tablete s oznakom „AV3“ na jednoj strani i „M“ na drugoj strani.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg tablets are yellow, oval, biconvex film-coated tablet marked with “AV2” on one side and “M” on the other side.
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg tablete su žute, ovalne, bikonveksne filmom obložene tablete s oznakom „AV2“ na jednoj strani i „M“ na drugoj strani.
Cardiac disorders
Poremećaj koordiancije
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Light yellow, round, approximately 9 mm diameter, biconvex film-coated tablet debossed with “AV1” on one side and “M” on the other side.
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Svjetložuta, okrugla, bikonveksna filmom obložena tableta promjera približno 9 mm s utisnutom oznakom „AV1“ na jednoj strani i „M“ na drugoj strani.